Dyne Therapeutics Inc [DYN] stock is trading at $7.85, up 5.09%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DYN shares have gain 15.27% over the last week, with a monthly amount drifted -36.23%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on March 12, 2025, when BMO Capital Markets initiated its Outperform rating and assigned the stock a price target of $50. Previously, Scotiabank started tracking the stock with Sector Outperform rating on March 07, 2025, and set its price target to $50. On December 13, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $46 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $45 on November 26, 2024. JP Morgan downgraded its rating to a Neutral and reduced its price target to $35 on October 24, 2024. Chardan Capital Markets reiterated a Buy rating for this stock on May 21, 2024, and upped its price target to $42. In a note dated April 30, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $40 on this stock.
Dyne Therapeutics Inc [DYN] stock has fluctuated between $6.36 and $47.45 over the past year. Currently, Wall Street analysts expect the stock to reach $47 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $7.85 at the most recent close of the market. An investor can expect a potential return of 498.73% based on the average DYN price forecast.
Analyzing the DYN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.49 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.51 points at the first support level, and at 7.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.10, and for the 2nd resistance point, it is at 8.35.
Ratios To Look Out For
For context, Dyne Therapeutics Inc’s Current Ratio is 15.60. Further, the Quick Ratio stands at 15.60, while the Cash Ratio is 10.3.
Transactions by insiders
Recent insider trading involved Friedl-Naderer Johanna, Chief Commercial Officer, that happened on Mar 13 ’25 when 143.0 shares were sold. SVP, Head of Finance & Admin., Scalzo Richard William completed a deal on Mar 11 ’25 to sell 1343.0 shares. Meanwhile, Chief Scientific Officer Beskrovnaya Oxana sold 2153.0 shares on Mar 11 ’25.
